Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial

Metabolic Syndrome and Related Disorders

Volumn 14, Issue 3, 2016, Pages 161-166

  Cicero, Arrigo F G ^a   Colletti, Alessandro ^a   Rosticci, Martina ^a   Cagnati, Marcella ^a   Urso, Riccardo ^a   Giovannini, Marina ^a   Borghi, Claudio ^a   D'Addato, Sergio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CASEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTOTRIPEPTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ISOLEUCYL-PROLYL-PROLINE; OLIGOPEPTIDE; VALYL-PROLYL-PROLINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL STIFFNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HIP CIRCUMFERENCE; HUMAN; MALE; MASS SPECTROMETRY; METABOLIC SYNDROME X; MIDDLE AGED; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD PRESSURE; COMPLICATION; DRUG EFFECTS; HYPERTENSION; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OLIGOPEPTIDES; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS;

EID: 84961789009     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2015.0093     Document Type: Article

References (33)

1. Bauer UE, Briss PA, Goodman RA, et al. Prevention of chronic disease in the 21st century: Elimination of the leading preventable causes of premature death and disability in the USA. Lancet 2014;384:45-52.
2. Elkind MS. Epidemiology and risk factors. Continuum 2011;17:1213-1232.
3. Gaciong Z, Siński M, Lewandowski J. Blood pressure control and primary prevention of stroke: Summary of the recent clinical trial data and meta-analyses. Curr Hypertens Rep 2013;15:559-574.
4. Mendis S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Prog Cardiovasc Dis 2010;53:10-14.
5. Doménech M, Roman P, Lapetra J, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: One-year randomized, clinical trial. Hypertension 2014;64:69-76.
6. Saneei P, Salehi-Abargouei A, Esmaillzadeh A, et al. Influence of Dietary Approaches to Stop Hypertension (DASH) diet on blood pressure: A systematic review and metaanalysis on randomized controlled trials. Nutr Metab Cardiovasc Dis 2014;24:1253-1261.
7. Houston M. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World J Cardiol 2014;6:38-66.
8. Sirtori CR, Arnoldi A, Cicero AF. Nutraceuticals for blood pressure control. Ann Med 2015;47:447-456.
9. Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep 2013;15:260-267.
10. Cicero AF, Gerocarni B, Laghi L, et al. Blood pressure lowering effect of lactotripeptides assumed as functional foods: A meta-analysis of current available clinical trials. J Hum Hypertens 2011;25:425-436.
11. FeketeaA, Givens DI, Lovegrove JA. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients 2015;7:659-681.
12. Cicero AF, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valineproline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens 2013;26:442-449.
13. Cicero AF, Rosticci M, Veronesi M, et al. Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: A randomized, double-blind, crossover clinical trial. J Med Food 2010;13:1363-1368.
14. Cicero AF, Rosticci M, Gerocarni B, et al. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or firstdegree hypertension: A randomized double-blind clinical trial. Hypertens Res 2011;34:1035-1040.
15. Cicero AF, Rosticci M, Ferroni A, et al. Predictors of the short-term effect of isoleucine-proline-proline/valineproline-proline lactotripeptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high-normal blood pressure or first-degree hypertension. Clin Exp Hypertens 2012;34: 601-605.
16. NCEP ATP III Expert Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
17. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision. Arterioscler Thromb Vasc Biol 2006;26:2186-2191.
18. Matsuura K, Mizuno S, Nishimura S, et al. Quantitative analysis of the antihypertensive peptides Val-Pro-Pro and Ile-Pro-Pro in casein hydrolyzate using an Aspergillus oryzae protease: An LC-MS method. Milchwissenschaft 2005;60:24-27.
19. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159-2219.
20. Hickson SS, Butlin M, Broad J, et al. Validity and repeatability of the Vicorder apparatus: A comparison with the SphygmoCor device. Hypertens Res 2009;32:1079-1085.
21. Pucci G, Cheriyan J, Hubsch A, et al. Evaluation of the Vicorder, a novel cuff-based device for the noninvasive estimation of central blood pressure. J Hypertens 2013;31:77-85.
22. Cicero AFG, Rosticci M, Parini A, et al. Serum uric acid is inversely proportional to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: Data from the Brisighella Heart Study. Intern Emerg Med 2014;9:655-660.
23. Day LM, Maki-Petaja KM, Wilkinson IB, et al. Assessment of brachial artery reactivity using the Endocheck: Repeatability, reproducibility and preliminary comparison with ultrasound. Artery Res 2013;7:119-120.
24. Jauhiainen T, Vapaatalo H, Poussa T, et al. Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 2005;18(12 Pt 1):1600-1605.
25. Nakamura T, Mizutani J, Sasaki K, et al. Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: A preliminary study. J Med Food 2009;12:1221-1226.
26. Jauhiainen T, Rönnback M, Vapaatalo H, et al. Long-term intervention with Lactobacillus helveticus fermented milk reduces augmentation index in hypertensive subjects. Eur J Clin Nutr 2010;64:424-431.
27. Yoshizawa M, Maeda S, Miyaki A, et al. Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 2009;297:H1899-H1903.
28. Hirota T, Ohki K, Kawagishi R, et al. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: Contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 2007;30:489-496.
29. Yoshizawa M, Maeda S, Miyaki A, et al. Additive beneficial effects of lactotripeptides intake with regular exercise on endothelium-dependent dilatation in postmenopausal women. Am J Hypertens 2010;23:368-372.
30. Malaguti M, Dinelli G, Leoncini E, et al. Bioactive peptides in cereals and legumes: Agronomical, biochemical and clinical aspects. Int J Mol Sci 2014;15:21120-21135.
31. Kajimoto O, Aihara K, Hirata H, et al. Hypotensive effects of the tablets containing "Lactotripeptides (VPP, IPP)". J Nutr Food 2001;4:51-61.
32. Ding F, Qian B, Zhao X, et al. VPPIPP and IPPVPP: Two hexapeptides innovated to exert antihypertensive activity. PLoS One 2014;8:e62384.
33. Cicero AF, Colletti A. Nutraceuticals and blood pressure control: Results from clinical trials and meta-analyses. High Blood Press Cardiovasc Dis 2015;22:203-213.